In this episode of The Insight, Jerry Lee, a managing director in the Global Healthcare Investment Banking Group, discusses how the golden age of biotechnology and the current capital raising environment has created a disconnect in the market’s ability to fund new innovation across the sector. Although the current macro environment has made public markets funding challenging overall, with biopharma is no exception – the outlook for both capital raising & strategic M&A in 2023 is more positive.
Source: Dealogic and CapIQ as of 9-Dec-22
Our weekly newsletter with insights and intelligence from across the firm
By submitting this information, you agree to receive marketing emails from Goldman Sachs and accept our privacy policy. You can opt-out at any time.